Press release
Gossamer Bio Announces GB004 Data Presentations at United European Gastroenterology Virtual Week 2020
SAN DIEGO--(BUSINESS WIRE)-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and
About this update from Gossamer Bio, Inc.
[{"type":"text","content":" SAN DIEGO--(BUSINESS WIRE)--\nGossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will present data relevant to GB004 at United European Gastroenterology Virtual Week 2020, which takes place from October 11th through 13th. This includes an oral presentation from William Sandborn, M.D., Chief of the Division of Gastroenterology of University of California San Diego, detailing clinical data from the completed GB004 Phase 1b trial in patients with active mild-to-moderate ulcerative colitis.\n\nDetails for presentations related to GB004, a HIF-1α stabilizer in clinical development for the treatment of inflammatory bowel disease, are as follows:\n\nSession Type: Moderated Poster Session\nSession Title: IBD Clinical II\nPoster Code: P0589\nPoster Title: Safety, Pharmacokinetic, Biomarker, Histologic, and Rectal Bleeding Activity Following Treatment with the Gut-Targeted, PHD-Inhibitor and HIF-1α Stabilizer GB004 in a Phase 1b Trial in Mild-to-Moderate Ulcerative Colitis\nPresenting Author: William Sandborn, M.D.\nDate: Sunday, October 11th\nTime: 3:40pm CEST / 9:40am EDT / 6:40am PDT\n\nSession Type: E-Poster Session\nSession Title: Poster Exhibition\nPoster Code: P0562\nPoster Title: GB004 exhibits protective effects directly on epithelial cells using ex vivo organoid and monolayer cultures\nPresenting Author: Kristen Taylor Meadows, Ph.D.\n\nAbout Gossamer Bio\n\nGossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Its goal is to be an industry leader in each of these therapeutic areas and to enhance and extend the lives of patients suffering from such diseases.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20201009005109/en/\n\nFor Investors and Media:\nBryan Giraudo, Chief Financial Officer\nGossamer Bio Investor Relations\[email protected]\n\nSource: Gossamer Bio, Inc.","length":3756,"tagName":"div"}]